Literature DB >> 32521298

Low expression of miR-20b-5p indicates favorable prognosis in laryngeal squamous cell carcinoma, especially in patients with non-infiltrated regional lymph nodes.

Theodwros-Leonidas Pantazis1, Aris I Giotakis2, Sotirios Karamagkiolas2, Ioannis Giotakis2, Manousos Konstantoulakis3, Aliki Liakea4, Evangelos P Misiakos5.   

Abstract

PURPOSE: Tumor recurrence and distant metastasis are very common in laryngeal squamous cell carcinoma (LSCC). In this study, we examined the potential prognostic value of microRNA-20b-5p (miR-20b-5p), a component of the tumor-related miR-106a/363 cluster.
MATERIALS AND METHODS: Total RNA was purified from 105 tissue specimens resected from patients having undergone surgical treatment for primary LSCC. After in vitro polyadenylation and reverse transcription, a sensitive real-time quantitative polymerase chain reaction (qPCR) methodology was applied for the relative quantification of miR-20b-5p levels. Then, we proceeded with biostatistical analysis, seeking to assess the prognostic value of miR-20b-5p expression in LSCC.
RESULTS: miR-20b-5p positivity constitutes a predictor of inferior DFS and OS in LSCC (P < 0.001 and P = 0.002, respectively). The significant prognostic value of miR-20b-5p expression status seems to be independent of tumor size, histological grade, and TNM stage, as revealed by the multivariate bootstrap Cox regression analysis. Kaplan-Meier survival analysis showed also that miR-20b-5p expression status can stratify LSCC patients with non-infiltrated regional lymph nodes (N0) into two subgroups with distinct prognosis (P = 0.004 and P = 0.004, respectively).
CONCLUSIONS: The miR-20b-5p expression status is a promising molecular tissue biomarker in LSCC, with an independent prognostic value, and thus merits further validation in larger cohorts of patients.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Head and neck cancer; Molecular tumor biomarker; Prognostic biomarker; Real-time quantitative PCR; microRNA (miRNA)

Year:  2020        PMID: 32521298     DOI: 10.1016/j.amjoto.2020.102563

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  2 in total

1.  MicroRNA-363-3p promote the development of acute myeloid leukemia with RUNX1 mutation by targeting SPRYD4 and FNDC3B.

Authors:  Yimin Chen; Shuyi Chen; Jielun Lu; Danyun Yuan; Lang He; Pengfei Qin; Huo Tan; Lihua Xu
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

Review 2.  Systematic review and meta-analysis of prognostic microRNA biomarkers for survival outcome in laryngeal squamous cell cancer.

Authors:  Yan Huang; Min Gu; Yiting Tang; Zhiqiang Sun; Judong Luo; Zhe Li
Journal:  Cancer Cell Int       Date:  2021-06-22       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.